Haisco Pharmaceutical (002653.SZ): Anruikefen Injection Added to National Reimbursement Drug List

Stock News12-08

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice on December 7, 2025, regarding the updated National Reimbursement Drug List (NRDL) for 2025. The company's Ciprofol Injection successfully renewed its inclusion, while Anruikefen Injection was newly added to the NRDL (2025 edition).

Anruikefen Injection is a self-developed, highly selective peripheral kappa opioid receptor (KOR) agonist. It is also the world's first non-controlled prescription opioid analgesic for pain management that does not require classification as a narcotic or psychotropic drug.

Currently, Haisco has four Class 1 innovative drugs included in the NRDL (2025 edition): Ciprofol Injection, Anruikefen Injection, Benzenesulfonic Acid Crelgabalin Capsules, and Koglitin Tablets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156457377?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 11:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156457377","market":"sh","top_or_hot":-1,"title":"Haisco Pharmaceutical (002653.SZ): Anruikefen Injection Added to National Reimbursement Drug List","media":"Stock News","content":"<p>Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice on December 7, 2025, regarding the updated National Reimbursement Drug List (NRDL) for 2025. The company's Ciprofol Injection successfully renewed its inclusion, while Anruikefen Injection was newly added to the NRDL (2025 edition).</p>\n<p>Anruikefen Injection is a self-developed, highly selective peripheral kappa opioid receptor (KOR) agonist. It is also the world's first non-controlled prescription opioid analgesic for pain management that does not require classification as a narcotic or psychotropic drug.</p>\n<p>Currently, Haisco has four Class 1 innovative drugs included in the NRDL (2025 edition): Ciprofol Injection, Anruikefen Injection, Benzenesulfonic Acid Crelgabalin Capsules, and Koglitin Tablets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haisco Pharmaceutical (002653.SZ): Anruikefen Injection Added to National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaisco Pharmaceutical (002653.SZ): Anruikefen Injection Added to National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 11:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice on December 7, 2025, regarding the updated National Reimbursement Drug List (NRDL) for 2025. The company's Ciprofol Injection successfully renewed its inclusion, while Anruikefen Injection was newly added to the NRDL (2025 edition).</p>\n<p>Anruikefen Injection is a self-developed, highly selective peripheral kappa opioid receptor (KOR) agonist. It is also the world's first non-controlled prescription opioid analgesic for pain management that does not require classification as a narcotic or psychotropic drug.</p>\n<p>Currently, Haisco has four Class 1 innovative drugs included in the NRDL (2025 edition): Ciprofol Injection, Anruikefen Injection, Benzenesulfonic Acid Crelgabalin Capsules, and Koglitin Tablets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1156457377","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156457377","pubTimestamp":1765166058,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice on December 7,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0239":"医药制造","BK0033":"西藏振兴","002653":"海思科","BK0188":"融资融券","BK0077":"质押式回购"},"translate_title":"海思科制药（002653.SZ）：安瑞可芬注射液新增国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002653":1},"content_text":"Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice on December 7, 2025, regarding the updated National Reimbursement Drug List (NRDL) for 2025. The company's Ciprofol Injection successfully renewed its inclusion, while Anruikefen Injection was newly added to the NRDL (2025 edition).\nAnruikefen Injection is a self-developed, highly selective peripheral kappa opioid receptor (KOR) agonist. It is also the world's first non-controlled prescription opioid analgesic for pain management that does not require classification as a narcotic or psychotropic drug.\nCurrently, Haisco has four Class 1 innovative drugs included in the NRDL (2025 edition): Ciprofol Injection, Anruikefen Injection, Benzenesulfonic Acid Crelgabalin Capsules, and Koglitin Tablets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156457377","isCrawlerRequest":true}